drugset / Trial / NCT07446101
A Study of Mirikizumab Solution (LY3074828) in Healthy Participants
RandomizedParallel-groupOpen-labelBasic science
Summary
The main purpose of this study is to assess the safety and tolerability of mirikizumab (LY3074828) solution formulation administered as a single injection compared with two injections under the skin in healthy participants. Blood tests will be performed to investigate how the body processes the study drug. For each participant, the study will last about 15 weeks.
Timeline
- Start
- 2026-03-24
- Primary completion
- 2027-02
- Completion
- 2027-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Mirikizumab | Monoclonal antibody | — | Subcutaneous |
Indications
No indication recorded.